Welcome

Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and
others concerned about HIV/AIDS. Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the
conversation yourself by registering on the left side of this page.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive
and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a
username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own
physician.

All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators
of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please
provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are
true and correct to their knowledge.

Author
Topic: Tivicay/Epzicom Switch Study (Read 3749 times)

We are pleased to announce the opening of a new one pill once/day study of Tivicay combined with epzicom called the "Switch" study. Tivicay is the new integrase inhibitor from GSK.

The new combo avoids the CNS toxicity of Atripla, the bone and kidney toxicity of Truvada, the lipodystrophy changes associated with Protease Inhibitors, and doesn't require ritonavir (or cobicistat) to shut down liver metabolism to boost blood levels. In short, this combo is arguably the best regimen for HIV ever developed.

The study is open to folks who are on their first or second HIV regimen. If you would be interested in receiving more information or setting up a screening visit to see if you are eligible, please contact Eileen Glutzer at 415-353-0212 or Eileen@QuestClinical.com

This note certainly talks up the wonders of Epzicom, but there are reasons why Truvada is the NRTI backbone of choice in the US -- not Epzicom -- even with the bone/kidney issues. Not taking anything away from Tivicay, but I wonder how popular this particular combo will prove to be.

I am in a similar european only study from ViiV. They are so convinced of Tivicay/Epzicom (Kivexa)that they didnt want to draw blood within the first 3 months. I was told that the Truvada side effects (kidneys, bones) dont happen with these drugs. The first 2 month went very well so far. Despite I wait for TAF, but it is not available yet.The problem of Epzicom is the necessary genetic test, or You can get an allergic shock.

Anyway, GSK has already a better drug than Tivicay in the Pipeline. The LATTE II study with monthly injections of GSK744 will start soon. It' s Your Chance if You are Treatment-naive, CD over200 and VL over 1.000. All others have to wait until 2020.